Qnovia
Manufacturing · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2920 W Broad St 243, Richmond, Virginia,...Phone Number
(973) 865-9982Website
www.qnovia.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Qnovia
Qnovia, Inc. is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs.Explore more
Qnovia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Qnovia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Qnovia had a recent Job posting/layoffs
Earning: See what the market has to say on Qnovia recently announced quarterly report
Check if Qnovia has recently received funding, and reach out quickly before it becomes old news!
Qnovia, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Qnovia launches new products
Check out if Qnovia is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Qnovia
Funding: Get notified immidiatlly once Qnovia has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Qnovia as Masked Content
Find 2 more new buyers
Compare Similar Companies to Qnovia
Compare insights from companies similar to Qnovia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Qnovia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Qnovia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Qnovia.
Qnovia financials insights
Gather financial insights about Qnovia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$17M
2024
Series B
$16M
Qnovia Tech Stack
A closer look at the technologies used by Qnovia
See more technologies
Most Recent Scoops
Open Position
Promotion
Executive Move
Qnovia has announced that Mario Danek has been promoted from Founder & Chief Technology Officer to the role of Founder & Chief Executive Officer.
Funding
Funding
Funding
Project
Branding
Qnovia News & Media
Qnovia's Inhaled Nicotine Replacement Therapy Delivers Positive Results in First Human Study
RespiRx ™ achieves cigarette-comparable nicotine delivery with favorable safety profile, marking first major advancement in smoking cessation in decades IRVINE, Calif., Feb. 10, 2026 /PRNewswire/ -- Qnovia, Inc., a pharmaceutical and medtech company revolutionizing inhaled therapeutics,...Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
- Company has raised $50 million since its inception - - Funds will advance RespiRx™ Nicotine Inhaler to Marketing Authorization Application (MAA) submission and accelerate the path to commercialization in the UK - RICHMOND, Va., Dec. 10, 2024 /PRNewswire/ -- Qnovia, Inc., a...Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
Speech highlights the need for inhalation-based prescription nicotine replacement therapy to address efficacy shortfalls of current treatment options RICHMOND, Va., Oct. 21, 2024 /PRNewswire/ -- Qnovia, Inc. announced its CEO is speaking publicly to FDA and NIH at the joint agency public...Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study will evaluate the pharmacokinetics, safety and tolerability of the RespiRx™ Nicotine Inhaler compared to Nicotrol® Inhaler and combustible cigarettes - RICHMOND, Va., Oct. 1, 2024...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Qnovia
Sign Up For FreeTo access detailed company insights
Qnovia, Inc. is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigat... Read More
